A private investment firm that was formed in 2001 to manage the capital of a successful entrepreneur and a concentrated, select group of other individuals and institutions is seeking to invest into privately held companies in the life science space. Because of the firm’s capital base, they have the ability to be highly flexible and move quickly with investment opportunities. The firm is currently focused on acquiring or investing in outstanding companies, co-investing with debt or equity sponsors, and committing capital to established third-party managers in the private and public markets. The firm can be flexible in terms of investment size and is open to reviewing opportunities from around the globe.

Within the Life Science space, the firm is primarily focused on companies in the healthcare and pharmaceutical services space where the firm has significant experience and expertise. That being said the firm is also open to reviewing early stage companies developing therapeutics, medical device, diagnostics and laboratory equipment. The firm is opportunistic across technology types and indications for these opportunities and will consider companies with products in pre-clinical stage of development to those that already have a product on the market.

The firm is looking for companies with experienced management teams and will seek a board seat on a case by case basis when it is appropriate to do so. The firm is generally more comfortable with co-investing in early stage opportunities although they are not completely opposed to leading a round if the right opportunity were to present itself.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large tech company is actively seeking investments in the life science space. The firm manages two venture funds worth a total of $1.1B; one of these funds focuses on early-stage companies, and the other targets companies of all sizes.  The firm is actively seeking new investment opportunities and is open to review opportunities from around the globe.

In the Life Sciences, the firm seeks to invest in Mobile healthcare IT, bio authentication, fitness and wellness measurement algorithm (i.e. Fitbit and Basis type of companies), calorie measurement, heart measurement, glucose measurement, and medical imaging equipment technology (i.e. Ultrasound, MRI, CAT scan, and image enhancement and distribution tech). The firm is open to reviewing companies of all stages.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital and hedge fund hybrid based in the Western United States is currently looking to make investments into biotech companies. The firm is looking to make investments ranging from $1-5 million generally in Seed and Series A rounds. The firm is open to reviewing opportunities from throughout the United States and Canada.

The firm is currently looking for companies working with therapeutics. The firm is open to reviewing both small molecules and biologics and in terms of indication is focused exclusively on oncology, in particular prostate cancer, and immunology. The firm is open to reviewing company’s at all therapeutic phases of development; however they prefer smaller valuations.

The firm is open to working with public or privately held companies and looks for companies with experienced management teams. The firm looks to add significant value in addition to capital including the expertise and connections of the firm’s partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel group that is made up entirely of healthcare professionals is seeking to invest in technologies that significantly advance the standard of care. The group considers companies at a range of stages and is geographically agnostic. Since the members are investing their own capital, the investment size and capital structure are highly flexible. The group is actively seeking new investment opportunities, and is open to leading financing rounds.

The group is interested in therapeutics, diagnostics, and medical devices. While the group will consider most any indication and technology type, the group currently has a particular interest in cell therapy and in the oncology sector. In general, the group is not interested in dermatology. The group will only consider products that have shown human clinical efficacy; in the case of therapeutics, the group generally looks at phase II companies but if a company has obtained human efficacy data in phase I, the group would consider the opportunity. 

The group invests in both private and public companies. The group performs deep scientific due diligence on all the opportunities that the group takes part in, often conducted by the group’s members.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a global science-based company active in health, nutrition and materials is interested in strategic investment opportunities.  The firm makes equity investments into seed and venture stage companies. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking to make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

The firm is looking for companies in the intersection of Life and Materials Sciences. These includes companies developing devices and materials targeting indications of cardiovascular, orthopedics, ophthalmology, dental, drug delivery and next generation cellular therapy. The firm is also interested in companies in the Agbio and nutraceutical spaces. While the firm has invested in companies all the way from seed to 3-month pre-IPO, they generally invest into companies that do not yet have a product on the market.

The firm highly values experience in a firm’s management team and generally looks to take a board seeks and play an active role in its portfolio companies. The firm is looking for companies that are in cooperation/alignment with the parent business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com